The Avastin vs Visudyne for Neovascular AMD Study

• Status: Withdrawn
• Trial end date: 1969-12-31
• Target enrollment: 0
• Participant gender: All

Summary

The object of the study is to compare the treatment effect of bevacizumab (Avastin), an antibody targeting vascular endothelial growth factor, with verteporfin photodynamic therapy (PDT) for patients with neovascular age-related macular degeneration, the leading cause of vision severe loss in the Western world.

• Phase: Phase 3
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: St. Erik Eye Hospital
• Treatments: Bevacizumab; Verteporfin

Criteria

Inclusion Criteria:

• patients with subfoveal neovascular AMD with either classic/predominantly classic or small occult lesions

• visual acuity >=0.1

Exclusion Criteria:

• patients with subfoveal neovascular AMD with minimally classic lesions or large occult lesions

• subfoveal hemorrhage (>1DA) or fibrosis

• patients previously treated for neovascular AMD in the study eye